Kuros Biosciences

Schlieren, Switzerland Founded: 2000 • Age: 26 yrs Listed
Provider of smart solutions for bone disease management

About Kuros Biosciences

Kuros Biosciences is a publicly listed company based in Schlieren (Switzerland) founded in 2000. Provider of smart solutions for bone disease management. Kuros Biosciences has raised $24.65 million across 7 funding rounds from investors including Optiver, European Union and Life Sciences Partners. The company has 4 employees. Kuros Biosciences has completed 1 acquisition, including Xpand Biotechnology. Its website kurosbio.com draws about 12 thousand monthly visits. Kuros Biosciences offers products and services including MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is Kuros Biosciences AG.

Company details

Kuros Bioscience is a provider of smart solutions for bone disease management. It has developed solutions to improve patient rehabilitation. It provides a MagnetOs, a unique bone graft with submicron surface topography, that harnesses the power of osteoimmunology to deliver uniform, solid and stable spinal fusions. It has also developed a Fibrin-PTH candidate that delivers targeted and controlled bone formation. It promotes bone formation through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The device is in clinical trial 2A stage FDA approved.

  • Headquarters Schlieren, Switzerland
  • Employees 4
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website kurosbio.com
  • Social LinkedIn Facebook Instagram YouTube
  • Legal Name Kuros Biosciences Ltd.
Operational Areas
Key Metrics
  • Annual Revenue
    $153.03 M (USD)
    61.74
    as on Dec 31, 2025
  • Net Profit
    $2.67 M (USD)
    as on Dec 31, 2025
  • EBITDA
    $12.78 M (USD)
    288.78
    as on Dec 31, 2025
  • Total Equity Funding
    $24.65M (USD)

    in 7 rounds

  • Latest Funding Round
    $6.24M (USD), Post-IPO

    Sep 2022

  • Investors
    Optiver

    & 11 more

  • Employee Count
    4
  • Investments & Acquisitions

Products & Services of Kuros Biosciences

Kuros Biosciences offers a comprehensive portfolio of products and services, including MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules.

MagnetOs
Bone Graft

Promotes bone growth for spinal fusions using advanced surface technology.

MagnetOs Easypack Putty
Bone Graft Material

Provides flexible bone graft solution for surgical applications.

MagnetOs Flex Matrix
Bone Graft Material

Enables predictable fusion in spinal procedures.

MagnetOs Putty
Bone Graft Material

Supports bone regeneration in soft tissue environments.

MagnetOs Granules
Bone Graft Material

Facilitates bone growth for fusion surgeries.

Apps and channels of Kuros Biosciences

its YouTube channel Kuros Biosciences has 215 subscribers and 30 videos.

Kuros Biosciences
YouTube 215 subscribers 30 videos Science & Technology
Open channel

Videos from Kuros Biosciences

The most watched videos on Kuros Biosciences's YouTube channel, Kuros Biosciences (215 subscribers). Click a video to play it here.

MagnetOs Granule under an ultra-high resolution scanning electron microscope (SEM)
1.4K views
Introducing MagnetOs MIS
1.1K views
Favorable Results of MagnetOs as Standalone Alternative to Autograft in a Level 1 Clinical Trial
924 views
MagnetOs Flex Matrix in the OR with Dr. Terrance Crowder
613 views

More on Kuros Biosciences.

Funding Insights of Kuros Biosciences

Kuros Biosciences has successfully raised a total of $24.65M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.24 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $24.65M
  • Total Rounds 7
  • Last Round Post-IPO β€” $6.24M
  • First Round $4.32M

    (Oct 2005)

  • Investors Count 12

All 7 funding rounds of Kuros Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2022$6.24MPost-IPO––
Jan 2021$490,543Grant––
Jan 2020$488,179Grant––
Jan 2019$16MPost-IPO––
–
Nov 2015$4.97MSeries B––
–
Aug 2015$15.35MSeries B–LifeCare Partners
Oct 2005$4.32MSeries A–NeoMed, DEFI Gestion
Valuation history

12 investors in total: 12 institutional.

Investors in Kuros Biosciences

Kuros Biosciences has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Optiver, European Union and Life Sciences Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
LifeCare Partners is involved in unspecified activities.
lifecare.partners
Private equity investments in life sciences businesses are managed.
1998lspvc.comAmsterdam, Netherlands
Early-stage venture capital is invested in US and Europe.
vipartners.chAltendorf, Switzerland
Venture capital firm
omegafunds.comBoston, United States
Stage-agnostic life sciences-focused VC firm investing in North America & Europe
neomed.netOslo, Norway
defigestion.ch
Market-making services for financial instruments are provided globally.
1986optiver.comAmsterdam, Netherlands
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Investments are made in Swiss SMEs for succession and growth.
1997renaissance.netLausanne, Switzerland
B2B portal for client imports, product management, and user account handling.
1988cdcentreprises.frParis, France
Premium access

Investor details for Kuros Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

IPO & Listings of Kuros Biosciences

Kuros Biosciences is a publicly listed company on the SIX with ticker symbol KURN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date31 Aug 2018
  • Listed onCSE: SPEY
  • Listed entityKuros Biosciences Ltd.
  • Exchange sectorHealth technology
  • ISINCH0325814116
  • Share price20.00 CHF (-0.6% on the day) · 2026-05-11
  • Market capitalisation792,969,064.00 CHF
  • Price to earnings434.8
  • EPS (diluted, trailing year)0.05 CHF
  • Volume (last session)48,700
  • Analyst consensusStrong buy

Financials of Kuros Biosciences

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025121.3M CHF2.1M CHF10.1M CHF
202475.0M CHF-4.3M CHF2.6M CHF
202333.6M CHF-13.7M CHF-2.6M CHF
202218.0M CHF-14.6M CHF-7.4M CHF
202113.8M CHF-7.5M CHF-6.1M CHF
Premium access

Detailed financial statements for Kuros Biosciences

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Kuros Biosciences

Kuros Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Xpand Biotechnology.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Mini-bioreactors are developed as alternatives to 2D cell culture systems.
xpand-biotech.comBilthoven, Netherlands2004Dec 2016$29M
Premium access

Complete acquisition details for Kuros Biosciences

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Kuros Biosciences

5 dated milestones of Kuros Biosciences across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded Kuros Biosciences is founded.
  2. Funding First funding round of $4.3M.
  3. Acquisition Acquires Xpand Biotechnology.
  4. IPO Lists on the stock exchange (IPO).
  5. Funding Latest funding round, Post-IPO, of $6.2M.

Web traffic of Kuros Biosciences

The website of Kuros Biosciences (kurosbio.com) receives about 12.1K visits a month.

  • Monthly visits
    12.1K

    ▲ 37% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Kuros Biosciences

Premium access

Complete news archive for Kuros Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kuros Biosciences

Kuros Biosciences was founded in 2000 and raised its 1st funding round 5 years after it was founded.

Kuros Biosciences is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.

Kuros Biosciences is a funded company, having raised a total of $24.65M across 7 funding rounds to date. The company's 1st funding round was a Series A of $4.32M, raised on Oct 2005.

Kuros Biosciences has 4 employees.

Annual revenue of Kuros Biosciences is $153.03M as on Dec 31, 2025.

Kuros Bioscience is a provider of smart solutions for bone disease management. It has developed solutions to improve patient rehabilitation. It provides a MagnetOs, a unique bone graft with submicron surface topography, that harnesses the power of osteoimmunology to deliver uniform, solid and stable spinal fusions. It has also developed a Fibrin-PTH candidate that delivers targeted and controlled bone formation. It promotes bone formation through the induction of osteoprogenitor cell differentiation, enhancement of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The device is in clinical trial 2A stage FDA approved.

Kuros Biosciences offers MagnetOs, MagnetOs Easypack Putty, MagnetOs Flex Matrix, MagnetOs Putty, and MagnetOs Granules.

Yes, Kuros Biosciences is publicly traded on SIX under the ticker symbol KURN.

Kuros Biosciences has made 1 acquisition, including Xpand Biotechnology.

Kuros Biosciences has 12 investors. Key investors include Optiver, European Union, Life Sciences Partners, LifeCare Partners, and VIP Partners.

Kuros Biosciences operates through Kuros Biosciences Ag.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available